Sinan Batman Appointed CTO of TeraRecon

Sinan Batman will be responsible for developing next-gen, AI-based advanced visualization and clinical workflow application technologies.

“Sinan shares our drive for better patient outcomes and value through out-of-the-box solutions for streamlined efficiency and effectiveness,” said Romesh Wadhwani, chairman and founder of parent company SymphonyAI. “He brings a track record of delivering value to customers by building and deploying innovative solutions that make analytics and decision support simple, ubiquitous, and transparent.”

Sinan Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems. At Fujifilm Medical Systems USA, he was Executive Technical Director of Research and Development, heading the core medical IT product development and leading 200 product releases. Batman directed the Digital Innovation and Data Science Teams at Hillrom, leading the development of class-leading health risk prediction algorithms across the care continuum.

Earlier In his career, Sinan Batman has developed computer-aided diagnosis algorithms for breast cancer detection and was one of the early scientists working on quantifying gene expression using microarray imaging technologies for the US National Institutes of Health. He developed advanced autonomous medical imaging algorithms for disease and target detection as a research scientist at Johns Hopkins University. Batman modeled, simulated, and optimized quantum-well laser diodes and arrays while working as a Research Scientist at Xerox Research Labs in a NASA-sponsored project.

“Time-to-value is an essential ingredient for product and technology success,” said Batman. “It takes more than sophisticated tools, like a high-quality AI platform, though that is a necessity. Success comes from the hard work of developing real solutions that business enterprises can see value from immediately. Solutions must use a nuanced understanding of how healthcare works. TeraRecon understands that and is leading the enterprise AI movement in healthcare as a result.”

SourceTeraRecon

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”